15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Inhibikase Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $4.00 to $8.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $5.40 sits 135% above the current $2.30. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.09 next quarter toward $-0.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Inhibikase Therapeutics Inc.
As of Jul, 6 of 6 firms rate IKT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IKT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.09
Range $-0.09 – $-0.09 · 2 analysts
Next period, 2 analysts expect Inhibikase Therapeutics Inc to earn $-0.09 a share (range $-0.09 – $-0.09), versus — a year earlier. Full-year consensus is $-0.37, growing to $-0.38 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $214.3K, rising to $285.7K next year.
Top analysts covering Inhibikase Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IKT.
#1
EW
Edward White
HC Wainwright & Co. · Rank #241
Hold
No targeton IKT
Overall win rate
31%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$8.00+247.8% to target
Overall win rate
37%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #360
Buy
$8.00+247.8% to target
Overall win rate
30%
+ Follow
#4
Aydin Huseynov
Ladenburg Thalmann · Rank #361
Buy
$4.00+73.9% to target
Overall win rate
34%
+ Follow
#5
Jason Zemansky
B of A Securities
Buy
$6.00+160.9% to target
Coverage
—
+ Follow
IKT stock forecast FAQ
What is IKT's average 12-month price target?+
The 4 analysts with a live target average $5.40 for Inhibikase Therapeutics Inc over the next 12 months, ranging from a $8.00 high to a $4.00 low.
Is IKT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IKT?+
The Street-high target is $8.00 (HC Wainwright & Co.), and the Street-low is $4.00 (Ladenburg Thalmann). The average of all 4 active targets is $5.40.
How many Wall Street analysts cover IKT?+
6 analysts have an active rating on Inhibikase Therapeutics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering IKT?+
Among analysts who currently cover IKT, Edward White of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #241). Their current call is Hold.
What is Inhibikase Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.09 per share (range $-0.09 – $-0.09) across 2 analysts. Full-year EPS is projected at $-0.37, rising to $-0.38 the following year.
How much revenue is Inhibikase Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $214.3K, growing to $285.7K next year.
Have analysts been upgrading or downgrading IKT lately?+
As of Jul, 6 of 6 firms rate IKT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IKT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
